Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

141. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials

Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

142. Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator

Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

143. Statin Intolerance ? Management Considerations

Statin Intolerance ? Management Considerations STATIN INTOLERANCE - MANAGEMENT CONSIDERATIONS BOTTOM LINE: PRACTICAL RECOMMENDATIONS ? Statins are the lipid lowering drugs with the best evidence for outcome benefit! ( ? Non-fatal MI, CV death & stroke & mortality) ? The amount of effort spent in persevering with statin therapy in patients with significant adverse effects should be related to their level of cardiovascular (CV) risk. 1(CCS 12) Those at higher CV risk stand to benefit more (...) ! ? For subjects at low risk of CV events who are intolerant to statin therapy, a re-evaluation of need for therapy should precede trial of an alternative therapy. 1(CCS 12) ? CK levels should be monitored at baseline and in those patients who develop myalgia while on a statin. 1(CCS 12) ? Having a high risk patient on a statin, irrespective of LDL levels achieved, has shown a reduction in CV events (multiple trials). 4S, CARDS,HPS 2,3,4,5,6,7,8,9 Allowing unmet LDL targets to drive therapy toward

2013 RxFiles

144. The Effectiveness of Statins for Primary Prevention: A Rapid Review

with statins, compared to placebo. (GRADE quality of evidence: low) The direction and magnitude of reduction in both major coronary events and stroke events was consistent across all 3 meta-analyses, despite differences in the definition of primary prevention populations. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Hydroxymethylglutaryl-CoA Reductase Inhibitorss; Primary Prevention Language Published English Country of organisation Canada Province or state Ontario English (...) The Effectiveness of Statins for Primary Prevention: A Rapid Review The effectiveness of statins for primary prevention: a rapid review The effectiveness of statins for primary prevention: a rapid review Schaink A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Schaink A. The effectiveness of statins for primary prevention: a rapid review

2013 Health Technology Assessment (HTA) Database.

145. Systematic review with meta-analysis: Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis

Systematic review with meta-analysis: Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins in patients with CKD prove beneficial in reducing cardiovascular events

2013 Evidence-Based Medicine

146. Randomised controlled trial: Statins induce hyperglycaemia of uncertain importance

Randomised controlled trial: Statins induce hyperglycaemia of uncertain importance Statins induce hyperglycaemia of uncertain importance | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins induce hyperglycaemia of uncertain importance Article Text Aetiology Randomised controlled trial Statins induce hyperglycaemia of uncertain importance Victor M Montori , Juan P Brito Statistics from Altmetric.com Commentary on: Ridker PM

2013 Evidence-Based Medicine

147. Systematic review with meta-analysis: Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease

Systematic review with meta-analysis: Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease | BMJ Evidence-Based Medicine We use cookies (...) Username * Password * your user name or password? You are here Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease Article Text Therapeutics Systematic review with meta-analysis Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short

2013 Evidence-Based Medicine

148. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease

of this assessment has been made for the HTA database. Citation NIHR HSC. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticholesteremic Agents; Azetidiness; Cardiovascular Diseases; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors Language Published English (...) Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2013 Health Technology Assessment (HTA) Database.

149. High dose versus standard dose statins in stable coronary heart disease

High dose versus standard dose statins in stable coronary heart disease July - August 2012 87 © Tel.: 604 822•0700 Fax: 604 822•0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 High dose versus standard dose statins in stable coronary heart disease The mean age of participants ranged from 60 to 64; 82 (...) % of participants were male, and 97% were Caucasian. The duration of follow-up ranged from a median of 4.8 years to a mean of 6.7 years. The standard doses in the three RCTs were atorvastatin 10 mg, simvastatin 20 mg and simvastatin 20-40 mg; the high doses were atorvastatin 40-80 mg, atorvastatin 80 mg and simvastatin 80 mg. The in- terventions tested in these RCTs were pre-specified statin doses, not pre-specified LDL-C targets. 12,13 All 3 RCTs were either fully or partially sponsored by the pharmaceutical

2013 Therapeutics Letter

150. Systematic review with meta-analysis: Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events

Systematic review with meta-analysis: Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers

2013 Evidence-Based Medicine

151. Review: Statins reduce pancreatitis in adults with normal or mildly elevated triglyceride levels. (Abstract)

Review: Statins reduce pancreatitis in adults with normal or mildly elevated triglyceride levels. 23247957 2013 04 12 2012 12 18 1539-3704 157 12 2012 Dec 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: statins reduce pancreatitis in adults with normal or mildly elevated triglyceride levels. JC6-8 10.7326/0003-4819-157-12-201212180-02008 Bloomfield Hanna E HE Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota, USA. eng Comment

2012 Annals of Internal Medicine

152. Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis

Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

153. Review: Statins decrease mortality and major CV events in adults with CKD not receiving dialysis. (Abstract)

Review: Statins decrease mortality and major CV events in adults with CKD not receiving dialysis. 23165680 2013 01 28 2012 11 20 1539-3704 157 10 2012 Nov 20 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: statins decrease mortality and major CV events in adults with CKD not receiving dialysis. JC5-4 10.7326/0003-4819-157-10-201211200-02004 Ramesh Prasad G V GV University of Toronto Toronto, Ontario, Canada. eng Comment Journal Article United States Ann Intern Med

2012 Annals of Internal Medicine

154. Statin use and reduced cancer-related mortality. Full Text available with Trip Pro

Statin use and reduced cancer-related mortality. A reduction in the availability of cholesterol may limit the cellular proliferation required for cancer growth and metastasis. We tested the hypothesis that statin use begun before a cancer diagnosis is associated with reduced cancer-related mortality.We assessed mortality among patients from the entire Danish population who had received a diagnosis of cancer between 1995 and 2007, with follow-up until December 31, 2009. Among patients 40 years (...) of age or older, 18,721 had used statins regularly before the cancer diagnosis and 277,204 had never used statins.Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.85 (95% confidence interval [CI], 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer. Adjusted hazard ratios for death from any cause according to the defined daily statin dose (the assumed average maintenance dose per day) were 0.82

2012 NEJM

155. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis

Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

156. Very early initiation of statin therapy and mortality in patients with acute coronary syndrome

Very early initiation of statin therapy and mortality in patients with acute coronary syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

157. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

158. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis

The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

159. Adjunctive Statin Therapy Improves Clinical Parameters in Initial Phase Treatment of Chronic Periodontitis

Adjunctive Statin Therapy Improves Clinical Parameters in Initial Phase Treatment of Chronic Periodontitis UTCAT2306, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Adjunctive Statin Therapy Improves Clinical Parameters in Initial Phase Treatment of Chronic Periodontitis Clinical Question Is adjunctive use of statins with scaling and root planing more effective than scaling and root planing alone in the treatment (...) of chronic periodontitis? Clinical Bottom Line Statin therapy (systemic or local delivery) may positively enhance the effect of non-surgical initial phase scaling and root planing therapy in the treatment of chronic periodontitis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Pradeep/2009 Chronic Periodontitis (n=60) Randomized Controlled Trial Key results The simvastatin treatment group resulted

2012 UTHSCSA Dental School CAT Library

160. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.